spacer
home > ebr > summer 2003 > the cognitive assessment of herbal products - are the effects imagined or real?
PUBLICATIONS
European Biopharmaceutical Review

The Cognitive Assessment of Herbal Products - Are the Effects Imagined or Real?

With the recent proposal by the EU Commission for a Directive on so-called 'traditional herbal products', it would seem that it is no longer possible for companies producing herbal products to simply put them in the marketplace. For years now, many herbal products have been marketed as cognitive enhancers or herbal antidepressants with little or no evidence to substantiate the claims except that they 'have been used traditionally for centuries'. The new EU Directive insists that any herbal products be treated as the medicines they claim to be, rather than seeking the protection of national food laws. Therefore, new and existing herbal compounds will be required to prove 'qualitative, efficacious and safe' results in structured clinical trials. The main disadvantage of the new law, which will have a major adverse impact on the trade of herbal remedies, is that products which cannot claim 30 years of established use will have to seek market authorisation as medicinal products. In this sense, the new Directive's ostensible intention to minimise cost burdens on small and medium-sized producers will also have the unpleasant effect of deleting several little-known herbal products from the EU market altogether.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tamsin Manktelow, Scientific Development Manager, and Andrea Zangara, Research Associate, at Cognitive Drug Research Ltd

Having graduated from the University of Reading with a BA Hons in Psychology, Tamsin Manktelow has worked as a Clinical Assistant with adolescents suffering from eating disorders, and as a Clinical Audit and Research Assistant.

She joined CDR in June 2000 as a Research Assistant and now oversees the academic arm as Scientific Development Manager. Tamsin is registered at the University of Northumbria for a part-time PhD studying the cognitive effects of eating disorders.

Andrea Zangara joined Cognitive Drug Research Ltd (CDR) in September 2000 having been a Research Assistant at University College London for a year. During this time Andrea researched the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions and has since published his work.

Currently, Andrea is a Research Associate at CDR and oversees a number of single and multi-centre projects. He is registered at the University of Northumbria for a part-time PhD examining the cognitive effects of Huperzine.

spacer
Tamsin Manktelow
spacer
spacer
spacer
Andrea Zangara
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement